EA
TEVA icon

Edge Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Edge Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,000
Closed -$37K – 942
2017
Q4 		$37K Hold
2,000
– – ﹤0.01% 570
2017
Q3 		$35K Hold
2,000
– – ﹤0.01% 562
2017
Q2 		$66K Buy
2,000
+937
+88% +$29K 0.01% 455
2017
Q1 		$34K Buy
1,063
+967
+1,007% +$33K ﹤0.01% 581
2016
Q4 		$3K Buy
+96
New +$3.83K ﹤0.01% 756

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Edge Advisors's TEVA Position: Q1 2018 in Review

Edge Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 2,000 shares — an estimated $37K sold.

Edge Advisors first reported a position in TEVA in Q4 2016 and held it in 5 quarters. The position peaked at $66K in Q2 2017. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Edge Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Edge Advisors sold 2,000 Teva Pharmaceuticals shares in Q1 2018, an estimated $37K.
  • Edge Advisors first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 5 quarters.
  • Edge Advisors's Teva Pharmaceuticals position peaked at $66K in Q2 2017.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Edge Advisors's 13F filing for Q1 2018, filed 15 May 2018.